- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00096382
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Treatment of Patients With Metastatic Melanoma Using a Transplant of Autologous Lymphocytes Reactive With Tumor Following a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy, Total Body Irradiation and Reconstitution With CD34+ Cells
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies, such as cellular adoptive immunotherapy, work in different ways to stimulate the immune system and stop tumor cells from growing. Autologous stem cell transplant may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy. Interleukin-2 may stimulate a person's lymphocytes to kill tumor cells. Combining chemotherapy, radiation therapy, and biological therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cyclophosphamide and fludarabine together with radiation therapy followed by cellular adoptive immunotherapy, autologous stem cell transplant, and interleukin-2 works in treating patients with metastatic melanoma.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
OBJECTIVES:
Primary
- Determine complete clinical tumor regression in patients with metastatic melanoma treated with a myeloablative lymphoid-depleting preparative regimen comprising cyclophosphamide, fludarabine, and total body irradiation followed by autologous tumor-reactive tumor-infiltrating lymphocyte infusion, autologous CD34+ stem cell transplantation, and low-dose or high-dose interleukin-2.
- Evaluate the safety of this regimen in these patients.
Secondary
- Determine the survival of the infused lymphocytes by analyzing the sequence of the variable region of the T-cell receptor or flow cytometry in patients treated with this regimen.
OUTLINE:
- Autologous stem cell collection: Patients receive filgrastim (G-CSF) subcutaneously (SC) twice daily for 8 days. Beginning on day 5 of G-CSF, patients undergo apheresis daily for up to 3 days. Patients may receive 1 additional course of G-CSF and apheresis or use stem cells stored from a prior stem cell harvest in order to obtain an adequate number of cells.
- Lymphocyte-depleting myeloablative preparative regimen: Patients receive cyclophosphamide intravenous (IV) over 1 hour on days -5 and -6 and fludarabine IV over 15-30 minutes on days -6 to -2. Patients also undergo total body irradiation on day -1.
- Autologous lymphocyte infusion: Patients receive autologous tumor-reactive tumor-infiltrating lymphocytes IV over 20-30 minutes on day 0* followed by G-CSF SC once daily until blood counts recover.
- Autologous stem cell transplantation: Patients receive autologous CD34+ stem cells IV on day 2.
Interleukin therapy: Patients are assigned to 1 of 2 cohorts, depending on whether they have received prior high-dose interleukin-2 (IL-2).
- Cohort 1 (patients who received prior high-dose IL-2): Beginning on day 0*, patients receive high-dose IL-2 IV over 15 minutes 3 times daily for up to 5 days (maximum of 15 doses).
- Cohort 3 (patients who have not received prior high-dose IL-2): Patients receive treatment as in cohort 1.
NOTE: *Day 0 is 1-4 days after the last dose of fludarabine.
Patients are evaluated at 4-6 weeks.
PROJECTED ACCRUAL: A total of 116 patients will be accrued for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
-
Bethesda, Maryland, Vereinigte Staaten, 20892-1201
- NCI - Surgery Branch
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
- Diagnosis of metastatic melanoma
- Measurable disease
- Resected or stable brain metastases are allowed
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Eastern Cooperative Oncology Group (ECOG) 0-1
Life expectancy
- At least 3 months
Hematopoietic
- See Immunologic
- Absolute neutrophil count > 1,000/mm^3 (without support of filgrastim [G-CSF])
- Platelet count > 100,000/mm^3
- Hemoglobin ≥ 8 g/dL (transfusion allowed)
- No coagulation disorders
Hepatic
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 times upper limit of normal
- Bilirubin ≤ 2 mg/dL (< 3 mg/dL in patients with Gilbert's syndrome)
- No hepatitis B or C
Renal
- Creatinine ≤ 1.6 mg/dL
Cardiovascular
- Left ventricular ejection fraction (LVEF) ≥ 45% by cardiac stress test*
- No active major cardiovascular illness as evidenced by stress thallium or other comparable test
- No myocardial infarction
- No cardiac arrhythmias NOTE: *For patients ≥ 50 years of age receiving high-dose interleukin-2 (IL-2) OR patients with a history of electrocardiogram (EKG) abnormalities, symptoms of cardiac ischemia, or arrhythmias
Pulmonary
- Forced expiratory volume 1 (FEV_1) ≥ 60% of predicted by pulmonary function test in patients with prolonged history of cigarette smoking or symptoms of respiratory dysfunction*
- No active major respiratory illness
- No obstructive or restrictive pulmonary disease NOTE: *For patients receiving high-dose IL-2 only
Immunologic
- No active major immunologic illness
- No active systemic infections
No primary or secondary immunodeficiency
Fully recovered immune competence after prior chemotherapy or radiotherapy as evidenced by both of the following:
- Absolute neutrophil count > 1,000/mm^3
- No opportunistic infections
- Human Immunodeficiency virus (HIV) negative
- Epstein-Barr virus positive
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for 4 months after study treatment
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
Chemotherapy
- At least 6 weeks since prior nitrosourea therapy
- No prior cyclophosphamide and fludarabine as part of a preparative regimen on National Cancer Institute (NCI) Surgery Branch adoptive cell therapy studies unless sufficient numbers of CD34+ stem cells (more than 2 x10^6/kg patient weight) have been obtained prior to the administration of chemotherapy
Endocrine therapy
- No concurrent systemic steroid therapy
Radiotherapy
- Not specified
Surgery
- See Disease Characteristics
- Prior minor surgery within the past 3 weeks allowed if recovered
Other
- Recovered from all prior therapy
- At least 30 days since prior systemic therapy
- No other concurrent experimental agents
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Sonstiges: TBI 200cGy + TIL +HD IL-2, prior IL-2
Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator. Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient. |
high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
Andere Namen:
10 mcg/kg/day daily subcutaneously until neutrophil count >1x10^9/1.
Andere Namen:
Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
60 mg/kg/day x 2 days intravenously over 1 hour
Andere Namen:
25 mg/m^2/day intravenous piggyback daily over 15-20 minutes for 5 days
Andere Namen:
Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
Andere Namen:
|
Sonstiges: TBI 200cGy + TIL +HD IL-2, No prior IL-2
Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator. Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient. |
high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
Andere Namen:
10 mcg/kg/day daily subcutaneously until neutrophil count >1x10^9/1.
Andere Namen:
Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
60 mg/kg/day x 2 days intravenously over 1 hour
Andere Namen:
25 mg/m^2/day intravenous piggyback daily over 15-20 minutes for 5 days
Andere Namen:
Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Clinical Tumor Regression
Zeitfenster: Every 4-6 weeks for up to 1 year, and then every 6 months for up to 5 years.
|
Tumor regression is defined as a complete response (CR) or partial response (PR) and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST).
Complete response is the disappearance of all target lesions.
Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.
|
Every 4-6 weeks for up to 1 year, and then every 6 months for up to 5 years.
|
Safety
Zeitfenster: 4 years
|
Here is the number of participants with adverse events.
For a detailed list of adverse events see the adverse event module.
|
4 years
|
Mitarbeiter und Ermittler
Mitarbeiter
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Neubildungen
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Neuroendokrine Tumoren
- Nävi und Melanome
- Melanom
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Agenten des peripheren Nervensystems
- Antivirale Mittel
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- Analgetika
- Agenten des sensorischen Systems
- Analgetika, nicht narkotisch
- Antirheumatika
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Antineoplastische Mittel, alkylierend
- Alkylierungsmittel
- Myeloablative Agonisten
- Aldesleukin
- Cyclophosphamid
- Fludarabin
- Fludarabinphosphat
- Interleukin-2
Andere Studien-ID-Nummern
- 040288
- 04-C-0288
- NCI-7025
- NCI-PRMC-P6273
- CDR0000393480
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Melanom (Haut)
-
Federal University of Health Science of Porto AlegreAbgeschlossenSkin-PickingBrasilien
-
Oystershell NVAbgeschlossen
-
University of Wisconsin, MilwaukeeAbgeschlossen
-
Utah State UniversityAktiv, nicht rekrutierendAbschürfungsstörung (Skin-Picking).Vereinigte Staaten
-
Jordi Gol i Gurina FoundationAbgeschlossen
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulAbgeschlossenSkin-PickingBrasilien
-
University of ChicagoAbgeschlossenTrichotillomanie | Skin-PickingVereinigte Staaten
-
University of ChicagoAbgeschlossenDermatillomanie | Pathologisches Skin Picking | Neurotische Exkoriation | Psychogene ExkoriationVereinigte Staaten
-
Karolinska InstitutetRegion StockholmAbgeschlossenTrichotillomanie | Abschürfungsstörung (Skin-Picking).Schweden
-
University of ChicagoRekrutierungTrichotillomanie (Hair-Pulling Disorder) | Skin-PickingVereinigte Staaten
Klinische Studien zur aldesleukin
-
National Cancer Institute (NCI)AbgeschlossenMetastasierendes Melanom | NierenzellkrebsVereinigte Staaten
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI); Chiron CorporationAbgeschlossenNierenkrebsVereinigte Staaten
-
Blumenthal Cancer Center at Carolinas Medical CenterUnbekannt
-
Cancer Biotherapy Research GroupUnbekanntLungenkrebsVereinigte Staaten
-
St. Anna KinderkrebsforschungUnbekannt
-
National Cancer Institute (NCI)Abgeschlossen
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)AbgeschlossenLymphomVereinigte Staaten
-
European Organisation for Research and Treatment...AbgeschlossenLeukämieFrankreich, Belgien, Niederlande, Italien, Österreich, Kroatien
-
Cancer Biotherapy Research GroupUnbekanntNierenkrebsVereinigte Staaten
-
University of Southern CaliforniaNational Cancer Institute (NCI)BeendetInhaliertes Interleukin-2 bei der Behandlung von Patienten mit metastasiertem oder inoperablem KrebsNicht näher bezeichneter erwachsener solider Tumor, protokollspezifischVereinigte Staaten